Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06394167
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-04-26
Brief Title:
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Vertex Pharmaceuticals Incorporated
Study Overview
Official Title:
A Phase 1 Randomized Double-blind Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety and Pharmacokinetics of Intravenous VX-993 in Healthy Adults
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability and pharmacokinetics PK of intravenously administered VX-993 at different doses in healthy participants
Detailed Description:
This clinical trial information was submitted voluntarily under the applicable law and therefore certain submission deadlines may not apply That is clinical trial information for this applicable clinical trial was submitted under section 402j4A of the Public Health Service Act and 42 CFR 1160 and is not subject to the deadlines established by sections 402j2 and 3 of the Public Health Service Act or 42 CFR 1124 and 1144
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None